Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 1, 1999, Pages 6-12

  Asselin, Barbara L ^a,b,c,d,e   Kreissman, Susan ^a,b   Coppola, David J ^a,b   Bernai, Samuel D ^a,b   Leavitt, Pearl R ^a,b   Gelber, Richard D ^a,b   Sallan, Stephen E ^a,b   Cohen, Harvey J ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e The Leukemia & Lymphoma Society   (United States)

Author keywords

Acute lymphoblastic leukemia; Asparaginase; Efficacy; Prognosis; Toxicity

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW CELL; CELL KILLING; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; HYPERAMYLASEMIA; HYPERSENSITIVITY REACTION; INFANT; LEUKEMIA CELL; MALE; PANCREATITIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; ESCHERICHIA COLI; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PECTOBACTERIUM CHRYSANTHEMI; POLYETHYLENE GLYCOLS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033067429     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199901000-00003     Document Type: Article

References (30)

1. Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970;25:306-20.
2. Kung FH, Nyhan WL, Cuttner J. et al. Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse. Cancer 1978;41:428-34.
3. Reaman GH, Ladisch S, Echelberger C, et al. Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia. Cancer 1980;45:3090-4.
4. Ortega JA, Nesbit ME, Donaldson MH, et al. L-asparaginase, vincristine and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 1977;37:535-40.
5. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-7.
6. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-63.
7. Land VJ, Schuster JJ, Pullen J, et al. Unexpectedly high incidence of allergic reactions with high dose (HD) weekly asparaginase (ASP) consolidation (cons) therapy (Rx) in children with newly diagnosed non-T. non-B acute lymphoblastic leukemia (ALL): a Pediatric Oncology Group (POG) study [abstract 834]. Proc Am Soc Clin Oncol 1989;8:215.
8. Ertel IJ, Nesbit ME, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res 1979;39:3893-6.
9. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1:9-13.
10. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from Escherichia coli. Cancer 1972;30:376-81.
11. King OY, Wilbur JR, Mumford DM, et al. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer 1974;33:611-4.
12. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to E. coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-83.
13. Uren JR, Ragin RC. Improvement in the therapeutic, immunological, and clearance properties of E. coli and Erwinia L-asparaginase by attachment of poly-DL-alanyl peptides. Cancer Res 1979;39:1927-33.
14. Kamisaki Y, Wada H, Yagura T, et al. Reduction in immunogenicity and clearance rate of E. coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 1981;216:410-4.
15. Kawamura K, Igarashi T, Fujii T, et al. Immune response to polyethylene glycol modified L-asparaginase in mice. Int Arch Allergy Appl Immunol 1985;76:324-30.
16. Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol L-asparaginase. Drug Metab Dispos 1986;14:349-52.
17. Kurtzberg J, Friedman H, Asselin B, et al. Use of polyethylene glycol-conjugated L-asparaginase (PEG-ASP) in pediatric patients with prior hypersensitivity to native L-asparaginase. (Abstract 848). Proc Am Soc Clin Oncol 1990;9:219.
18. Kurtzberg J, Asselin B, Pollack B, et al. Peg-L-asparaginase (PEGasp) versus native E. coli asparaginase for reinduction of relapsed acute lymphoblastic leukemia: POG #886 phase II trial. (Abstract 1079). Proc Am Soc Clin Oncol 1993;12:325.
19. Abshire T, Pollock B, Billett A, et al. Weekly polyethylene glycol conjugated (PEG) L-asparaginase (ASP) produces superior reinduction remission rates in childhood relapsed acute lymphoblastic leukemia (rAII): a Pediatric Oncology Group (POG) study #9310. (Abstract 1038). Proc Am Soc Clin Oncol 1995;14:344.
20. Ettinger LJ, Kurtzberg J, Voûte PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-81.
21. Ettinger LJ, Lerner ED. A toxicity study of oncaspar (PEG-asparaginase) in children with acute lymphoblastic leukemia (ALL). (Abstract 354). Med Pediatr Oncol 1994;23:278.
22. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 1994;12:740-7.
23. Asselin BL, Ryan D, Frantz CN, et al. In-vitro and in-vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989;49:4363-8.
24. Kretschmar C, Berna S, Chen LB, et al. Measurement of leukemic cell kill in untreated childhood acute lymphoblastic leukemia after single agent methotrexate treatment [abstract]. Proc Am Assoc Cancer Res 1984;25:190. Abstract 752.
25. Frei E III, Sallan SE. Acute lymphoblastic leukemia: treatment. Cancer 1978;42:828-38.
26. Pieters R, Loonen AH, Huismans DR, et al. In-vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990;76:2327-36.
27. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetics studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-6.
28. Asselin BL, Scudiery D, Chen R, et al. Pharmacokinetics and pharmacodynamic analysis of PEG-L asparaginase in newly diagnosed pediatric patients with acute lymphoblastic leukemia. (Abstract 45). Pharmacotherapy 1992;12:502.
29. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparaginase in children with advanced leukemia. Cancer 1972;30:339-47.
30. Haskell CM, Canellos GP, Levanthal BG, et al. L-Asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281:1028-34.